|
- The dawn of China biopharma innovation | McKinsey
In this article, we take the pulse of China’s vibrant innovation ecosystem, look at the key trends driving the biopharma industry, and share thoughts on how multinational pharmaceutical players can tap into innovation opportunities in the world’s second-largest healthcare market
- 为中国生物制药行业再建“创新之桥” – McKinsey Greater China
作者：麦肯锡全球资深董事合伙人乐诚铎（Franck Le Deu） 2014年，当我们希望以某个框架来梳理中国生物制药市场的未来时
- China biopharma Charting a path to value creation Chi
What is the 5-10 years outlook for the China innovative biopharma market? China contributes 3% of the global innovative biopharma market, highlighting a significant opportunity for growth
- China Healthcare Summit 2025 - BioCentury
This October, BioCentury, BayHelix and Insights Partner McKinsey Company invite you to visit Shanghai for the 12th China Healthcare Summit Get a firsthand look at China's biotech ecosystem and build your network with the right biopharmas, investors and CDMOs
- McKinsey Company’s annual #ChinaBiopharma report 2024 titled . . .
This would make China the third largest innovative drug market by 2028, only after the US and Europe
- China biopharma – Charting a path to value creation - BioCentury
For its 10th China Summit report, McKinsey Company takes stock of the China biopharma industry's progress on value creation and decodes how it can create a sustainable impact on the global biopharma industry
- China’s innovation engine picks up spe - mckinsey. de
1 Seek Chinese universities as innovation partners ie in shanzhai (“copycat”) innovation But that picture is changing rapidly, with the best universities starting to recruit the world’s top faculty talent for priority disciplines and creating an en
- Vision 2028: How China could impact the global biopharma industry
Biopharmas in China have accelerated innovation Although many developments and drugs are still in their early stages, they show great promise for the future of the industry in China and the world
|
|
|